Characteristics associated with COVID-19 vaccine uptake among adults aged 50 years and above in England (8 December 2020-17 May 2021): a population-level observational study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
01 03 2022
Historique:
entrez: 2 3 2022
pubmed: 3 3 2022
medline: 8 3 2022
Statut: epublish

Résumé

To determine characteristics associated with COVID-19 vaccine coverage among individuals aged 50 years and above in England since the beginning of the programme. Observational cross-sectional study assessed by logistic regression and mean prevalence margins. COVID-19 vaccinations delivered in England from 8 December 2020 to 17 May 2021. 30 624 257/61 967 781 (49.4%) and 17 360 045/61 967 781 (28.1%) individuals in England were recorded as vaccinated in the National Immunisation Management System with a first dose and a second dose of a COVID-19 vaccine, respectively. Vaccination status with COVID-19 vaccinations. Proportion, adjusted ORs and mean prevalence margins for individuals not vaccinated with dose 1 among those aged 50-69 years and dose 1 and 2 among those aged 70 years and above. Of individuals aged 50 years and above, black/African/Caribbean ethnic group was the least likely of all ethnic groups to be vaccinated with dose 1 of the COVID-19 vaccine. However, of those aged 70 years and above, the odds of not having dose 2 was 5.53 (95% CI 5.42 to 5.63) and 5.36 (95% CI 5.29 to 5.43) greater among Pakistani and black/African/Caribbean compared with white British ethnicity, respectively. The odds of not receiving dose 2 was 1.18 (95% CI 1.16 to 1.20) higher among individuals who lived in a care home compared with those who did not. This was the opposite to that observed for dose 1, where the odds of being unvaccinated was significantly higher among those not living in a care home (0.89 (95% CI 0.87 to 0.91)). We found that there are characteristics associated with low COVID-19 vaccine coverage. Inequalities, such as ethnicity are a major contributor to suboptimal coverage and tailored interventions are required to improve coverage and protect the population from SARS-CoV-2.

Identifiants

pubmed: 35232787
pii: bmjopen-2021-055278
doi: 10.1136/bmjopen-2021-055278
pmc: PMC8889452
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e055278

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Brain Behav Immun. 2021 May;94:41-50
pubmed: 33713824
Euro Surveill. 2012 Apr 26;17(17):
pubmed: 22551493
Vaccine. 2018 May 31;36(23):3231-3238
pubmed: 29716775
Age Ageing. 2020 Aug 24;49(5):701-705
pubmed: 32402088
Lancet. 2021 May 8;397(10286):1711-1724
pubmed: 33939953
Wellcome Open Res. 2020 May 6;5:88
pubmed: 32613083
BMJ. 2021 Feb 18;372:n421
pubmed: 33602672
Euro Surveill. 2012 Apr 19;17(16):
pubmed: 22551460
Br J Gen Pract. 2021 Dec 31;72(714):e51-e62
pubmed: 34750106
Vaccine. 2017 Apr 25;35(18):2372-2378
pubmed: 28363324
Psychol Med. 2020 Dec 11;:1-15
pubmed: 33305716
Euro Surveill. 2017 Apr 27;22(17):
pubmed: 28488997
EClinicalMedicine. 2021 Jan;31:100674
pubmed: 33319186
Vaccine. 2020 Nov 17;38(49):7789-7798
pubmed: 33109389
Vaccine. 2015 May 21;33(22):2620-8
pubmed: 25835576

Auteurs

Elise Tessier (E)

Immunisation and Countermeasures Division, Public Health England, London, UK elise.tessier@phe.gov.uk.

Yuma Rai (Y)

Immunisation and Countermeasures Division, Public Health England, London, UK.

Eleanor Clarke (E)

Immunisation and Countermeasures Division, Public Health England, London, UK.

Anissa Lakhani (A)

Immunisation and Countermeasures Division, Public Health England, London, UK.

Camille Tsang (C)

Immunisation and Countermeasures Division, Public Health England, London, UK.

Ashley Makwana (A)

Vaccines and Countermeasures Division, Public Health England, London, UK.

Heather Heard (H)

Health Intelligence Division, Health Improvement Directorate, Public Health England, York, UK.

Tim Rickeard (T)

Vaccines and Countermeasures Division, Public Health England, London, UK.

Shreya Lakhani (S)

Immunisation and Countermeasures Division, Public Health England, London, UK.

Partho Roy (P)

Immunisation and Countermeasures Division, Public Health England, London, UK.

Michael Edelstein (M)

Faculty of Medicine, Bar-Ilan University, Safed, Israel.

Mary Ramsay (M)

Immunisation and Countermeasures Division, Public Health England, London, UK.

Jamie Lopez-Bernal (J)

Immunisation and Countermeasures Division, Public Health England, London, UK.

Joanne White (J)

Immunisation and Countermeasures Division, Public Health England, London, UK.

Nick Andrews (N)

Immunisation and Countermeasures Division, Public Health England, London, UK.

Colin N J Campbell (CNJ)

Immunisation and Countermeasures Division, Public Health England, London, UK.

Julia Stowe (J)

Immunisation and Countermeasures Division, Public Health England, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH